Psilocybin and OCD: What This Early Clinical Study Found

Obsessive-compulsive disorder (OCD) is a long-term mental health condition that can be exhausting to live with. It often involves intrusive, unwanted thoughts and repetitive behaviors that feel hard to control. While standard treatments like therapy and medication help many people, they do not work well for everyone, and some people continue to struggle for years.

A recent early-stage clinical trial explored whether psilocybin, a psychedelic compound found in certain mushrooms, could offer another path for treatment-resistant OCD. The study tested safety, symptom changes, and how people responded over time.

How the Psilocybin OCD Clinical Trial Was Conducted

This trial was designed carefully in a clinical hospital setting with medical supervision.

Participants:

• Had moderate to severe OCD
• Had already tried at least one standard treatment without enough relief
• Were monitored closely for safety and symptom changes

The study was conducted in two phases. In the first phase, participants were randomly assigned to receive either a placebo, a low dose of psilocybin, or a higher dose. In the second phase, all participants eventually received repeated higher-dose psilocybin sessions, allowing researchers to observe outcomes after multiple exposures over time.

In total, some participants received up to eight guided psilocybin sessions over several weeks. Each session took place in a controlled setting with trained staff supporting preparation, the experience itself, and follow-up integration.

Researchers tracked OCD symptoms using a standard clinical rating system and followed participants for six months after treatment ended.

Key Findings From the Psilocybin OCD Study

1. Safety and Side Effects of Psilocybin in OCD

Overall, psilocybin was generally well tolerated in this controlled setting.

• No serious medical or psychiatric emergencies were reported
• Common short-term effects included headache, nausea, fatigue, and emotional release
• Some participants experienced brief increases in anxiety or unusual perceptions during sessions, but these were temporary
• No psychotic symptoms were observed

This suggests that, under professional supervision, repeated psilocybin sessions can be physically and psychologically manageable for many participants.

2. How Psilocybin Affected OCD Symptoms

Many participants showed meaningful reductions in OCD symptoms over the course of treatment.

By the end of the treatment period:

• About 73% of participants showed a strong reduction in symptoms
• About 40% reached a level considered remission (minimal or no clinically significant OCD symptoms)
• Improvements often appeared quickly and continued during the treatment period

3. Long-Term Effects and Six-Month Follow-Up Results

The study followed participants for six months after treatment to understand whether improvements lasted beyond the active dosing period. Overall, results suggested a pattern of meaningful and, in many cases, sustained improvement in OCD symptoms after the final session. Many participants maintained much lower symptom levels compared to where they started, with several continuing to meet criteria for significant improvement and some remaining in remission at follow-up.

A notable finding was that participants who received more total psilocybin sessions tended to show stronger and more durable reductions in symptoms. In other words, greater cumulative exposure was associated with better outcomes, both at the end of treatment and, for some individuals, at the six-month mark.

The overall direction of results pointed toward lasting symptom relief for a substantial portion of the group. This consistency of improvement over time adds to early evidence that repeated, structured psilocybin sessions may have the potential to produce effects that extend beyond the immediate treatment window.

What This Means for Future OCD Treatment Options

Taken together, the findings point toward a treatment approach that involves more than symptom reduction alone. Researchers observed that participants who described deeper emotional experiences during sessions, such as feeling more open, connected, or experiencing a sense of psychological release, were often the same individuals who showed the greatest improvements in OCD symptoms. This suggests that the quality of the experience itself may play an important role in outcomes, alongside the biological effects of psilocybin.

More broadly, the results support a growing understanding in psychedelic research that healing may come from both the direct effects of the compound and the way people process and integrate the experience afterward. In this study, those two elements appeared to work together, pointing toward a potentially meaningful direction for future OCD treatment research focused on structured, supportive therapeutic experiences rather than medication alone.

Source: Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder. Journal of Psychopharmacology. 2026;0(0). doi:10.1177/02698811261424214